Illustration of SpaceOAR Hydrogel


SpaceOAR™ Hydrogel

SpaceOAR Hydrogel Evidence Summary

Creating more space between the prostate and rectum can result in a significant reduction in rectal radiation.1 This reduction in rectal radiation can help reduce late rectal toxicity, which can improve quality of life.2


US Pivotal Trial. 73% less rectal radiation, 75% less rectal toxicity, better quality of life




Get in touch with our team

Whether you're looking to get started with SpaceOAR Hydrogel or have general questions about the product, procedure or clinical data, our team is here to help.
Doctor in surgery

SpaceOAR™ Hydrogel is associated with lower rectal toxicity and higher bowel quality of life in long-term follow-up3

Systematic review & meta-analysis




SpaceOAR Hydrogel has been shown to help minimize side effects4

73% relative reduction in rectal V70, 0% late grade 2+ rectal toxicity, 70% less decline in bowel quality of life, 60% reduced likelihood of decline in urinary quality of life,  67% retained sexual function

Frequently Asked Questions

We've got the answers.


Get SpaceOAR Hydrogel

Become a certified applier.


Sign Up

Get exclusive updates and clincial data.


Real-world data shows how different treatment approaches can utilize SpaceOAR Hydrogel


Early Tolerance and Tumor Control Outcomes with High-Dose Ultrahypofractionated Radiation Therapy for Prostate Cancer
By: Zelefsky MJ, Pinitpatcharalert A, Kollmeier M, et al.


A Multi-Institutional Phase 2 Trial of High-Dose SAbR for Prostate Cancer Using Rectal Spacer
By: Folkert MC, Zelefsky MJ, Hannan R, et al. 


Dosimetric Feasibility of Neurovascular Bundle-Sparing Stereotactic Body Radiotherapy with Periprostatic Hydrogel Spacer for Localized Prostate Cancer to Preserve Erectile Function
By: Hwang ME, Mayeda M, Shaish H, et al.


Expanding the Utilization of Rectal Spacer Hydrogel for Larger Prostate Glands (>80cc): Feasibility and Dosimetric Outcomes
By: Fagundes M, Rodrigues MA, Olszewski S, et al. 
Rectal Hydrogel Spacer Improves Late Gastrointestinal Toxicity Compared to Rectal Balloon Immobilization After Proton Beam Radiotherapy for Localized Prostate Cancer: A Retrospective Observational Study
By: Dinh TT, Lee HJ, Macomber MW, et al.


SpaceOAR Vue™ Hydrogel: The Next-Generation Radiopaque Hydrogel Spacer
By: Brenneman RJ, Baumann BC


SpaceOAR Hydrogel spacer injection prior to stereotactic body radiation therapy for men with localized prostate cancer
By: Payne HA, Pinkawa M, Peedell Cl, et al.

Role for Rectal Spacer in the Radiotherapeutic Management of Prostate Cancer

Michael J. Zelefsky, MD, presents the Role for Rectal Spacer in the Radiotherapeutic Management of Prostate Cancer on Grand Rounds in Urology




200+ SpaceOAR Hydrogel publications

SpaceOAR Vue Hydrogel

A next-generation hydrogel spacer that offers enhanced visibility

  1. Quinn TJ, Daignault-Newton S, Bosch W, et al. Who benefits from a prostate rectal spacer? Secondary analysis of a Phase III trial. Pract Radiat Oncol. 2020 May-Jun;10(3):186-94.
  2. Hamstra DA, Mariados N, Sylvester J, et al. Continued benefit to rectal separation for prostate radiation therapy: Final results of a phase III trial. Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):976-85.
  3. Miller LE, Efstathiou JA, Bhattacharyya SK, et al. Association of the placement of a perirectal hydrogel spacer with the clinical outcomes of men receiving radiotherapy for prostate cancer: a systematic review and meta-analysis. JAMA Netw Open. 2020 Jun;3(6):e208221.
  4. Hamstra DA, Mariados N, Sylvester J, et al. Sexual quality of life following prostate intensity modulated radiation therapy (IMRT) with a rectal/prostate spacer: Secondary analysis of a phase 3 trial. Pract Radiat Oncol. 2018;8(1):e7-e15.
  5. Mariados N, Sylvester J, Shah D, et al. Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal  spacer application in men undergoing prostate image guided intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):971-7.
  6. Data on file with Boston Scientific.
Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.
CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.
SpaceOAR and SpaceOAR Vue Hydrogels are intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceOAR and SpaceOAR Vue Hydrogels to reduce the radiation dose delivered to the anterior rectum.
SpaceOAR and SpaceOAR Vue Hydrogels contain polyethylene glycol (PEG). SpaceOAR Vue Hydrogel contains iodine.
Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions and potential adverse events.
As with any medical treatment, there are some risks involved with the use of SpaceOAR and SpaceOAR Vue Hydrogels. Potential complications associated with SpaceOAR and SpaceOAR Vue Hydrogels include, but are not limited to: pain associated with SpaceOAR and SpaceOAR Vue Hydrogels injection, pain or discomfort associated with SpaceOAR and SpaceOAR Vue Hydrogels, local inflammatory reactions, infection (including abscess), urinary retention, urgency, constipation (acute, chronic, or secondary to outlet perforation), rectal tenesmus/muscle spasm, mucosal damage, ulcers, fistula, perforation (including prostate, bladder, urethra, rectum), necrosis, allergic reaction (localized or more severe reaction, such as anaphylaxis), embolism (venous or arterial embolism is possible and may present outside of the pelvis, potentially impacting vital organs or extremities), syncope and bleeding. The occurrence of one or more of these complications may require treatment or surgical intervention. URO-989811-AB.
All images are the property of Boston Scientific. All trademarks are the property of their respective owners.